DD298056A5 - Arzneimittel - Google Patents

Arzneimittel Download PDF

Info

Publication number
DD298056A5
DD298056A5 DD90343919A DD34391990A DD298056A5 DD 298056 A5 DD298056 A5 DD 298056A5 DD 90343919 A DD90343919 A DD 90343919A DD 34391990 A DD34391990 A DD 34391990A DD 298056 A5 DD298056 A5 DD 298056A5
Authority
DD
German Democratic Republic
Prior art keywords
thioredoxin
cells
cell
interleukin
bsf
Prior art date
Application number
DD90343919A
Other languages
German (de)
English (en)
Inventor
Anders Rosen
Original Assignee
Aktiebolaget Astra,Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktiebolaget Astra,Se filed Critical Aktiebolaget Astra,Se
Publication of DD298056A5 publication Critical patent/DD298056A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DD90343919A 1989-09-12 1990-09-10 Arzneimittel DD298056A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8903003A SE8903003D0 (sv) 1989-09-12 1989-09-12 Novel medical use

Publications (1)

Publication Number Publication Date
DD298056A5 true DD298056A5 (de) 1992-02-06

Family

ID=20376862

Family Applications (1)

Application Number Title Priority Date Filing Date
DD90343919A DD298056A5 (de) 1989-09-12 1990-09-10 Arzneimittel

Country Status (12)

Country Link
EP (1) EP0489113A1 (xx)
JP (1) JPH05500216A (xx)
AU (1) AU641942B2 (xx)
CA (1) CA2065454A1 (xx)
DD (1) DD298056A5 (xx)
FI (1) FI921058A0 (xx)
GR (1) GR1001151B (xx)
HU (1) HUT62932A (xx)
IE (1) IE903233A1 (xx)
PT (1) PT95284A (xx)
SE (1) SE8903003D0 (xx)
WO (1) WO1991004320A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
WO1998000160A1 (en) * 1996-06-28 1998-01-08 Nat Jewish Ct Immun & Respirat USE OF THIOREDOXIN-LIKE MOLECULES FOR INDUCTION OF MnSOD TO TREAT OXIDATIVE DAMAGE
US6689775B2 (en) 1999-06-03 2004-02-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Uses of thioredoxin
EP0946192A1 (en) * 1996-12-06 1999-10-06 Garth Powis Uses of thioredoxin
US5919657A (en) * 1997-04-09 1999-07-06 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human thioredoxin protein; related reagents
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
US6566514B1 (en) 1998-01-30 2003-05-20 Genesense Technologies Inc. Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
DE69939939D1 (de) 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
KR20010103655A (ko) 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
WO2002016600A2 (en) * 2000-08-25 2002-02-28 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004024868A2 (en) 2002-09-10 2004-03-25 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
WO2014145735A2 (en) 2013-03-15 2014-09-18 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633295B2 (ja) * 1987-06-12 1997-07-23 味の素株式会社 ヒトａｄｆをコードする遺伝子

Also Published As

Publication number Publication date
JPH05500216A (ja) 1993-01-21
IE903233A1 (en) 1991-03-27
HUT62932A (en) 1993-06-28
CA2065454A1 (en) 1991-03-13
FI921058A0 (fi) 1992-03-11
EP0489113A1 (en) 1992-06-10
HU9200821D0 (en) 1992-05-28
SE8903003D0 (sv) 1989-09-12
WO1991004320A1 (en) 1991-04-04
PT95284A (pt) 1991-08-14
GR900100679A (en) 1992-01-20
AU641942B2 (en) 1993-10-07
GR1001151B (el) 1993-05-24
AU6433690A (en) 1991-04-18

Similar Documents

Publication Publication Date Title
Snyder et al. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production.
Valiante et al. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation
Steeg et al. Regulation of murine macrophage Ia antigen expression by an immune interferon-like lymphokine: inhibitory effect of endotoxin.
Kim et al. Transforming growth factor-beta 1 is a costimulator for IgA production.
DE69526728T2 (de) VERWENDUNG VON IL-12 UND IL-12 ANTAGONISTEN zur Herstellung eines Arzneimittels FÜR BEHANDLUNG VON AUTOIMMUNKRANKHEITEN
Campbell et al. Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1.
Triantaphyllopoulos et al. Amelioration of collagen‐induced arthritis and suppression of interferon‐γ, interleukin‐12, and tumor necrosis factor α production by interferon‐β gene therapy
DD298056A5 (de) Arzneimittel
Klapal et al. Changes in neuronal excitability by activated microglia: differential Na+ current upregulation in pyramid-shaped and bipolar neurons by TNF-α and IL-18
Richards et al. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function
DD241271A5 (de) Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro
DE69131450T2 (de) Regulierung der immunoglobulinproduktion durch interleukin-9
AU621046B2 (en) Method for therapy of leukemias and certain other malignancies
Roodman et al. Tumor necrosis factor α and the anemia of chronic disease: Effects of chronic exposure to TNF on erythropoiesis in vivo
JPH01502980A (ja) ガンマインターフェロンと抗炎症剤または抗発熱剤との組合せ並びに疾患処置方法
AU607000B2 (en) Thymic stroma-derived t cell growth factor and the production
Claasen et al. A cell culture system that enhances mononuclear cell IgE synthesis induced by recombinant human interleukin-4
DE3818054C2 (de) Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
Nakoinz et al. Stimulation of macrophage antibody-dependent killing of tumor targets by recombinant lymphokine factors and M-CSF
US6713053B1 (en) Use of IL-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular
KR100225322B1 (ko) 종양괴사인자와 인터루킨-4의 상승작용 조성물
Boltz-Nitulescu et al. Augmentation of IgE receptor expression and IgE receptor-mediated phagocytosis of rat bone marrow-derived macrophages by murine interferons.
De Ojeda et al. Polyerga, a biological response modifier enhancing T-lymphocyte-dependent responses
Bowers et al. Conditioned medium from activated rat macrophages and the recombinant factors, IL-1β and GM-CSF, enhance the accessory activity of dendritic cells
Maino et al. Induction of interleukin 2 from a murine B cell tumor by a factor found in immune serum.

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee